Adamas Announces New Employment Inducement Grant
September 12 2018 - 4:30PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted six new employees the option to purchase an aggregate of
68,251 shares of the company’s common stock, at a per share
exercise price of $22.76, the closing trading price on September
10, 2018, and restricted stock units to acquire 11,373 shares of
the company’s common stock. The stock options and restricted stock
units vest over four years and were granted pursuant to the Adamas
Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by
the company's board of directors in March 2016 under Rule
5653(c)(4) of the Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the company.
About Adamas Pharmaceuticals,
Inc.Adamas’ goal is to create and commercialize a new
generation of medicines intended to lessen the burden of chronic
neurologic diseases on patients, caregivers and society using its
deep understanding of time-dependent biology. The company is
focused on the commercial launch of GOCOVRI™ (amantadine) extended
release capsules (previously ADS-5102), the first and only
FDA-approved medicine for the treatment of dyskinesia in patients
with Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications, and delivering on its
pipeline of differentiated investigational programs. Those programs
include: ADS-5102 in development for the treatment of multiple
sclerosis walking impairment; and ADS-4101, a high-dose, modified
release lacosamide in development for the treatment of partial
onset seizures in patients with epilepsy. For more information
about Adamas and its unique approach to developing medicines based
on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Oct 2023 to Oct 2024